Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The current study investigated several factors that might increase the risk of mortality in elderly patients with hip fracture. 3 key findings →

Design: meta-analysis Participants: 223,875 Evidence: high

CCT proved effective in PD-MCI patients when compared with traditional PCT. 4 key findings →

Design: randomized controlled trial Participants: 53 Evidence: high

Combined multi-domain interventions may contribute to preventing or delaying disease progression. 1 key finding →

Design: randomized controlled trial Participants: 33 Evidence: high

Between the two versions (paper-based vs. digital) statistically significant correlations were found in all tests, e.g., TMT-A r(48) = 0.63, p < 0.01; TMT-B rs(48) = 0.77, p < 0.001). 5 key findings →

Evidence: high

Despite the relatively low risk reduction associated with higher adherence to MedDiet among elderly, it should be considered that this population is the most affected. 3 key findings →

Design: meta-analysis Participants: 65,955 Evidence: moderate

One-year repeated cycles of cognitive training (CT) for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Aging clinical and experimental research 2013-06-20

Present results suggest that repeated cycles of CT in patients with AD treated with ChEIs are associated with benefits in several areas of cognitive function. 3 key findings →

Design: randomized controlled trial Participants: 16 Evidence: high

Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. 4 key findings →

Participants: 27 Evidence: high

Our findings demonstrated a significant association between plasma NFL levels and disrupted WM microstructure across the brain. 5 key findings →

Design: cross-sectional Participants: 92 Evidence: moderate

We observed high levels of missing data in most cognitive test items - on average 13% and as high as 65%. 5 key findings →

Design: longitudinal study Participants: 9,755 Evidence: moderate

The sample consisted predominantly of women (79% in the intervention group, 69% in the control group), with daughters forming the largest caregiver subgroup (66.6% and 52.4%, respectively). 5 key findings →

Design: randomized controlled trial Participants: 42 Evidence: high

A lack of understanding of the causes of attrition in longitudinal studies of older adults may lead to higher attrition rates and bias longitudinal study results. 4 key findings →

Design: longitudinal study Participants: 30,433 Evidence: moderate

) had a 14% increase in the rate of dementia incidence (HR 1.14, 95% CI 1.06-1.23; P <.001), and each standard deviation (SD) decrease in eBMD was associated with a 49% increase in dementia risk (HR 1.49, 95% CI 1.19-1.86; P <.001). 5 key findings →

Design: cohort study Participants: 131,030 Evidence: moderate

Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with dementia and is a serious concern for the health of individuals and government health care systems worldwide. 5 key findings →

Design: cross-sectional Evidence: moderate

The burden perceived by caregivers of patients with dementia is a fundamental prognostic aspect in the history of the disease. 4 key findings →

Design: cross-sectional Evidence: low

Oral diseases have emerged as one of the most prevalent non-communicable diseases (NCDs) worldwide, with a high global average prevalence of 45%, affecting an estimated 3.5 billion people globally. 1 key finding →

Evidence: low

Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68). 5 key findings →

Participants: 241 Evidence: low

The MI group significantly improved in attention-executive functioning (p = 0.003) compared to ACI (Cohen's d: 0.47, 95% CI 0.13-0.79). 5 key findings →

Evidence: low

The tests qualitatively and statistically associated to a cognitive decline are MMSE, FAB, BSTR, AM, and VSF, of which at least three were considered the most informative also by machine learning. 73% average accuracy was obtained in the diagnosis prediction on three subsets of original and external data. 3 key findings →

Participants: 281 Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed